Pemigatinib improves first-line activity in FGFR2-rearranged cholangiocarcinoma, but FIGHT-302 ended in a different treatment era
The phase III FIGHT-302 trial gives pemigatinib a stronger evidentiary footing in FGFR2-rearranged cholangiocarcinoma, where targeted therapy has long been attractive but difficult to test cleanly against a shifting standard of care. In the study, the FGFR inhibitor improved progression-free survival and response rates versus first-line chemotherapy in patients with advanced-stage disease carrying FGFR2 rearrangements. Those efficacy signals matter because this molecular subgroup is uncommon, biologically distinct, and clinically aggressive, leaving patients dependent on a narrow set of treatment options once first-line therapy is needed.
A sharper problem emerged outside the efficacy readout. Accrual moved slowly, and the trial closed early after chemoimmunotherapy became the new standard of care. That sequence turned FIGHT-302 into more than a drug story; it became a case study in how quickly oncology evidence can lose its clean comparator when practice changes midstream.
A biomarker-defined disease that needs biomarker-defined evidence
FGFR2-rearranged cholangiocarcinoma is the kind of malignancy that seems tailor-made for precision oncology. The disease is rare, the target is biologically coherent, and the therapeutic logic is straightforward: interrupt the aberrant signaling that helps drive tumor growth. In principle, that should make development faster, not slower. In practice, rarity fragments enrollment, limits geography, and forces investigators to recruit across many centers for a population small enough that a single trial can struggle to stay open long enough to answer the most important questions.
Pemigatinib’s activity against chemotherapy in FIGHT-302 supports the idea that molecular selection can enrich for meaningful benefit in advanced biliary tract cancer. The result is especially relevant because advanced cholangiocarcinoma is not a disease where incremental gains are trivial. Patients often have limited reserve, and cytotoxic chemotherapy can be difficult to tolerate over time. A targeted oral inhibitor that extends disease control and produces more responses changes the therapeutic conversation, even before overall survival is known.
Yet the trial’s early closure complicates interpretation. Once chemoimmunotherapy became standard first-line therapy, the control arm no longer reflected the regimen most clinicians would now consider current practice. A comparison against chemotherapy alone can still be informative, but it no longer answers the most urgent question at the bedside: where pemigatinib fits relative to the modern first-line mix, including immunotherapy-based combinations.
Why progression-free survival still matters here
Progression-free survival retains real clinical value in cholangiocarcinoma, where tumor growth can quickly translate into biliary obstruction, liver dysfunction, pain, and repeated hospitalizations. Delaying progression can preserve performance status and create a longer window for subsequent therapy. Response rate also matters because shrinkage can relieve symptoms and sometimes stabilize anatomy enough to keep patients eligible for additional treatment.
The signal from FIGHT-302 therefore carries biological plausibility. FGFR2 rearrangements activate a driver pathway that is actionable in a way many other cholangiocarcinoma alterations are not. Blocking that pathway can suppress proliferative signaling and, when the drug works, it should work in the kind of direct, on-target fashion that produces measurable tumor regression. That kind of effect is exactly what precision oncology promises when the biomarker and the drug are tightly matched.
One sentence captures the trial’s dilemma.
The drug worked against the old comparator, but the field moved before the trial could fully mature.
Trial slowdown exposes the limits of conventional development models
FIGHT-302 now sits alongside two similarly terminated trials as evidence that standard phase III development can be a poor fit for rare biomarker-defined cancers. Slow accrual is not just an operational inconvenience; it can distort the balance between scientific rigor and clinical relevance. When a study is designed around a comparator that later becomes obsolete, continuing enrollment may prolong uncertainty without necessarily improving the answer clinicians need.
That creates pressure for more adaptive approaches. Innovative trial designs could make better use of limited patients, faster biomarker screening, and evolving standard-of-care assumptions. Basket structures, platform methods, external controls, and more flexible statistical plans are all possible responses, provided they preserve enough validity to support decision-making. In rare cancers, the bar is not lower; the design has to be smarter.
Regulatory frameworks may need to move in parallel. A biomarker-defined therapy can be clinically compelling even when the classic phase III path becomes difficult to execute in full. If the comparator shifts during accrual, regulators and sponsors need a way to judge whether the totality of evidence still supports access without forcing patients into outdated trial architectures. The challenge is not unique to cholangiocarcinoma, but FIGHT-302 makes it especially visible.
What this means for FGFR2-directed therapy
For clinicians, the practical message is twofold. First, FGFR2 rearrangements remain a meaningful therapeutic target in advanced cholangiocarcinoma, and pemigatinib has demonstrated activity against first-line chemotherapy in the phase III setting. Second, the evidence base was assembled under conditions that no longer mirror routine care. That matters when sequencing therapy, counseling patients, and interpreting how much confidence to place in the result relative to newer first-line regimens.
For drug developers, the lesson is more structural. Precision oncology will keep generating small, molecularly defined populations in which the old one-trial, one-comparator model becomes increasingly fragile. If trial design cannot keep pace with the speed of therapeutic change, promising agents may either take too long to prove themselves or be judged against standards that no longer exist by the time the data read out.
The remaining question is not whether FGFR2 inhibition has value in cholangiocarcinoma. It does. The open question is how future studies will prove where that value belongs once the first-line benchmark keeps moving.